First-in-Human Trial of Radioligand Therapy for HER2-Positive Cancers Launches

A first-in-human trial has begun evaluating an innovative radioligand therapy targeting HER2-positive cancers. No efficacy or safety data are yet available.

• The trial is an early-phase study assessing a novel radioligand therapy in patients with HER2-expressing tumors.
• Radioligand therapy combines a targeting molecule with a therapeutic radioisotope to deliver radiation selectively to cancer cells.
• Because this is a trial launch announcement, no clinical outcomes or adverse event rates are reported.

RadPigeon summaries are original and for information only. They are not clinical advice.